Axsome Therapeutics, Inc. (AXSM) Form 8-K — Jun 9, 2026
Axsome Therapeutics, Inc. filed an 8-K reporting the adoption of its Executive Severance and Change in Control Plan, effective June 5, 2026. The plan establishes severance benefits for key employees, including named executive officers, upon involuntary termination or in connection with a change in control. The plan supersedes all prior severance agreements and arrangements.
Price after filing
1 day: +0.3%7 days: +2.6%30 days: -0.0%
Close on the filing date to close N calendar days later (from $245.64). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.